Phase I Evaluation of the Safety and Immunogenicity of an Investigational Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naïve Adults 50 - 70 Years of Age
Latest Information Update: 07 Aug 2019
At a glance
- Drugs TV 005 (Primary)
- Indications Dengue
- Focus Adverse reactions
Most Recent Events
- 07 Aug 2019 New trial record